MétaCan
Menu
Back to cohort
Record W4416593441 · doi:10.2196/88251

Protocol of Trials within Cohorts on the Integrated traditional Chinese and western medicine in the treatment of chronic spontaneous urticaria (Preprint)

2025· article· en· W4416593441 on OpenAlexvenueno aff
Linhao Li, Sihan Wang, Jiale Chen, Xiaojie Ding, Yifei Wang, Fei Guo, Xiaoying Sun, Liu Liu, Xin Li

Bibliographic record

VenueJMIR Research Protocols · 2025
Typearticle
Languageen
FieldMedicine
TopicUrticaria and Related Conditions
Canadian institutionsnot available
Fundersnot available
KeywordsCohortItchingWestern medicineTraditional Chinese medicineProtocol (science)Clinical trialAlternative medicine

Abstract

fetched live from OpenAlex

Abstract Background Chronic spontaneous urticaria (CSU) is a common inflammatory skin disease characterized by severe itching and wheals, affecting approximately 1.4% of the global population. Both second-generation H1-antihistamines and omalizumab have limited efficacy in some patients. Previous studies suggest that combining traditional Chinese medicine with biological agents may improve efficacy and reduce adverse effects in inflammatory skin diseases. Objective This study uses a trials within cohorts (TwiCs) design to evaluate the efficacy and safety of the shenqi formula (SQF) combined with omalizumab for the treatment of CSU. Methods This TwiCs study is built upon an existing urticaria cohort established in November 2019 at Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine. Overall, 92 eligible patients with type 1 autoallergic CSU and qi and blood deficiency syndrome will be randomly allocated in a 1:1 ratio to receive either omalizumab alone or omalizumab combined with the SQF. The treatment period is 24 weeks, followed by 16 weeks of follow-up. The primary outcome is the 7-day Urticaria Activity Score. Data will be managed using Microsoft Excel (version 2016), analyzed with SPSS (version 27.0; IBM Corp), and visualized with GraphPad Prism (version 9.0). A complier average causal effect analysis will be applied to estimate causal effects using generalized linear latent mixed models. Results As of the manuscript submission (November 2025), the trial has been funded (December 2024) and registered with the International Traditional Medicine Clinical Trial Registry (registered January 28, 2025). Patient enrollment commenced in April 2025 and is projected to conclude by December 2027. Data analysis is expected to be completed by June 2028, with final results anticipated for publication in the fourth quarter of 2028. Conclusions This study is the first to apply a TwiCs design to compare the efficacy and safety of SQF combined with omalizumab versus omalizumab alone in patients with CSU. The findings are expected to provide high-quality real-world evidence for the integration of traditional Chinese medicine with biological therapy in the management of CSU and to serve as a methodological reference for future TwiCs applications in dermatology research.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.045
metaresearch head score (Gemma)0.038
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Protocol · Consensus signal: Protocol
Teacher disagreement score0.045
Threshold uncertainty score0.239

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0450.038
Meta-epidemiology (narrow)0.0030.002
Meta-epidemiology (broad)0.0040.005
Bibliometrics0.0010.002
Science and technology studies0.0030.002
Scholarly communication0.0030.002
Open science0.0020.002
Research integrity0.0050.005
Insufficient payload (model declined to judge)0.0370.010

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.203
GPT teacher head0.521
Teacher spread0.318 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreProtocol

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueJMIR Research ProtocolsSame topicUrticaria and Related ConditionsFrench-language works237,207